| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| clozapine | Oral Liquid, suspension | 50 mg/mL | Current | Unavailable | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 3/11/2025 |
| bleomycin sulfate | Injection, powder for | 15000 IU | Anticipated | Available | Manufacturing | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | 1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .125 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/11/2025 |
| saxagliptin~dapagliflozin propanediol monohydrate | Tablet | 5 mg~12.3 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/11/2025 |
| dinoprostone | Gel | .3333 mg/g | Anticipated | Available | Manufacturing | 1/11/2025 |
| betiatide | Injection, powder for | 1 mg | Anticipated | Available | Manufacturing | 31/10/2025 |
| phenylephrine hydrochloride | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 31/10/2025 |
| phenoxymethylpenicillin potassium | Oral Liquid, powder for | 28.284 mg/mL | Resolved | Available | Manufacturing | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 31/10/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| escitalopram oxalate | Tablet, film coated | 25.548 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Unexpected increase in consumer demand | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 31/10/2025 |
| bimatoprost | Eye Drops | .3 mg/mL | Current | Unavailable | Manufacturing | 31/10/2025 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| irbesartan | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 31/10/2025 |
| irbesartan | Tablet, film coated | 150 mg | Anticipated | Available | Manufacturing | 31/10/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 20 mg~6.935 mg | Anticipated | Available | Manufacturing | 31/10/2025 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Unavailable | Manufacturing | 31/10/2025 |
| ambrisentan | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| lorazepam | Tablet | 1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 31/10/2025 |
| hyoscine butylbromide | Injection, solution | 20 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| daptomycin | Injection, powder for | 500 mg | Current | Limited Availability | Manufacturing | 31/10/2025 |
| fentanyl citrate | Injection, solution | 785 microgram | Resolved | Available | Manufacturing | 31/10/2025 |
| famciclovir | Tablet, film coated | 250 mg | Resolved | Available | Manufacturing | 31/10/2025 |
| famciclovir | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 31/10/2025 |
| lidocaine hydrochloride monohydrate | Injection, solution | 10 mg/mL | Resolved | Available | Manufacturing | 31/10/2025 |
| lidocaine hydrochloride monohydrate | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 31/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .25 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 31/10/2025 |
| lamotrigine | Tablet, dispersible | 200 mg | Anticipated | Available | Manufacturing | 31/10/2025 |
| rifampicin | Oral Liquid | 20 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 30/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 30/10/2025 |
| mesalazine | Tablet, modified release | 1 g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 30/10/2025 |
| lansoprazole | Capsule, enteric | 30 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| metronidazole | Tablet, uncoated | 400 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| naproxen | Oral Liquid, suspension | 25 mg/mL | Resolved | Available | Manufacturing | 30/10/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Manufacturing | 30/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .75 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .375 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | 1.5 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | 2.25 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 12.5 mg~300 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| atenolol | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Anticipated | Available | Manufacturing | 30/10/2025 |
| erlotinib hydrochloride | Tablet, film coated | 27.32 mg | Current | Unavailable | Unexpected increase in consumer demand | 30/10/2025 |
| carvedilol | Tablet, film coated | 6.25 mg | Resolved | Available | Manufacturing | 30/10/2025 |
| thiotepa | Injection, powder for | 15 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/10/2025 |
| thiotepa | Injection, powder for | 100 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/10/2025 |
| thiotepa | Injection, powder for | 400 mg | Current | Unavailable | Commercial Changes / Commercial viability | 30/10/2025 |
| Teriparatide | Injection, solution | .25 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/10/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| mianserin hydrochloride | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| methyldopa sesquihydrate | Tablet, film coated | 283 mg | Current | Limited Availability | Manufacturing | 30/10/2025 |
| pamidronate disodium | Injection, concentrated | 3 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/10/2025 |
| nizatidine | Capsule | 300 mg | Anticipated | Available | Manufacturing | 30/10/2025 |
| simvastatin | Tablet, film coated | 5 mg | Anticipated | Available | Manufacturing | 30/10/2025 |
| verapamil hydrochloride~trandolapril | Tablet, film coated | 240 mg~4 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| calcium polystyrene sulfonate | Powder | 999.3 mg/g | Anticipated | Available | Manufacturing | 29/10/2025 |
| risperidone | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| pentetic acid | Injection, powder for | 5 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| sildenafil citrate | Tablet, uncoated | 35.1 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 29/10/2025 |
| ceftazidime pentahydrate | Injection, powder for | 2.328 g | Current | Limited Availability | Manufacturing | 29/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Current | Unavailable | Unexpected increase in consumer demand | 29/10/2025 |
| temozolomide | Capsule, hard | 5 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| sodium nitroprusside | Injection, solution | 50 mg | Anticipated | Available | Manufacturing | 29/10/2025 |
| tobramycin | Capsule, hard | 28 mg | Anticipated | Available | Manufacturing | 29/10/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| atorvastatin calcium trihydrate~amlodipine besilate | Tablet, film coated | 43.376 mg~13.88 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| phenoxymethylpenicillin potassium | Tablet, film coated | 560 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| mesalazine | Tablet, enteric coated | 800 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 29/10/2025 |
| hydrocortisone | Tablet, uncoated | 4 mg | Current | Limited Availability | Manufacturing | 29/10/2025 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| risperidone | Tablet, film coated | .5 mg | Anticipated | Available | Commercial Changes / Commercial viability | 29/10/2025 |
| risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/10/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/10/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/10/2025 |
| risperidone | Tablet, film coated | 4 mg | Current | Unavailable | Commercial Changes / Commercial viability | 29/10/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 29/10/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 29/10/2025 |
| lurasidone hydrochloride | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| amiodarone hydrochloride | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| spironolactone | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| lenalidomide | Capsule | 5 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| sugammadex sodium | Injection, solution | 217.6 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| hydrocortisone hydrogen succinate | Injection, powder for | 127.6 mg | Anticipated | Available | Manufacturing | 29/10/2025 |
| levothyroxine sodium | Tablet | 50 microgram | Resolved | Available | Unexpected increase in consumer demand | 29/10/2025 |
| levothyroxine sodium | Tablet | 100 microgram | Resolved | Available | Unexpected increase in consumer demand | 29/10/2025 |
| sodium chloride | Injection, intravenous infusion | 9 g/L | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 29/10/2025 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 29/10/2025 |
| labetalol hydrochloride | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Unavailable | Manufacturing | 29/10/2025 |
| amoxicillin sodium | Injection, powder for | 1060 mg | Resolved | Available | Manufacturing | 29/10/2025 |
| Rubella virus~Measles virus~live varicella vaccine~Mumps virus | Injection, powder for | 1000 CCID50~1000 CCID50~1995 PFU~25119 CCID50 | Resolved | Available | Manufacturing | 28/10/2025 |
| prazosin hydrochloride | Tablet, uncoated | 2.19 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 28/10/2025 |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 28/10/2025 |
| salbutamol sulfate | Inhalation, conventional | 6 mg | Current | Unavailable | Manufacturing | 28/10/2025 |
| stannous chloride~etifenin | Injection, powder for | .42 mg~20 mg | Current | Unavailable | Manufacturing | 28/10/2025 |
| Somatropin | Injection, powder for | 12 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 28/10/2025 |
| hydrocortisone sodium succinate | Injection, powder for | 134 mg | Resolved | Available | Manufacturing | 28/10/2025 |
| enalapril maleate | Tablet | 5 mg | Current | Limited Availability | Manufacturing | 28/10/2025 |
| alfentanil hydrochloride | Injection, solution | 1.0876 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 28/10/2025 |
| doxylamine succinate | Tablet, uncoated | 25 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/10/2025 |
| quetiapine fumarate | Tablet, modified release | 57.5 mg | Anticipated | Available | Unexpected increase in consumer demand | 28/10/2025 |
| peramivir | Injection, concentrated | 10 mg/mL | Anticipated | Available | Commercial Changes / Commercial viability | 28/10/2025 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/10/2025 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Resolved | Available | Manufacturing | 28/10/2025 |
| Interferon gamma1b | Injection, solution | 4 million IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/10/2025 |
| risperidone | Injection, modified release | 50 mg | Anticipated | Available | Manufacturing | 28/10/2025 |
| Insulin glulisine | Injection, solution | 3.49 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/10/2025 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Resolved | Available | Manufacturing | 27/10/2025 |
| simvastatin~ezetimibe | Tablet | 80 mg~10 mg | Anticipated | Available | Manufacturing | 27/10/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Anticipated | Available | Manufacturing | 27/10/2025 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/10/2025 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 27/10/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 27/10/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 10.341 mg~10 mg | Resolved | Available | Manufacturing | 27/10/2025 |
| emtricitabine~tenofovir disoproxil succinate | Tablet, film coated | 200 mg~300.6 mg | Current | Limited Availability | Manufacturing | 27/10/2025 |
| pentamidine isetionate | Injection, powder for | 300 mg | Anticipated | Available | Manufacturing | 27/10/2025 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 27/10/2025 |
| GluureaLys(ahx)hbedCC | Injection, powder for | 25 microgram | Current | Unavailable | Manufacturing | 27/10/2025 |
| GluureaLys(ahx)hbedCC | Injection, powder for | 25 microgram | Current | Unavailable | Manufacturing | 27/10/2025 |
| iotroxate meglumine | Injection, solution | 105.46 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 27/10/2025 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/10/2025 |
2025年11月3日